Equities Analysts Set Expectations for KYMR FY2025 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at Leerink Partnrs dropped their FY2025 earnings per share estimates for Kymera Therapeutics in a research note issued to investors on Tuesday, November 4th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($3.63) per share for the year, down from their previous estimate of ($3.61). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics’ Q4 2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.99) EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.03) EPS and FY2026 earnings at ($4.09) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The business had revenue of $2.76 million for the quarter, compared to analysts’ expectations of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%.

A number of other research analysts have also weighed in on the company. The Goldman Sachs Group raised Kymera Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 15th. Citigroup increased their target price on Kymera Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Barclays upped their price target on shares of Kymera Therapeutics from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday. Oppenheimer reaffirmed an “outperform” rating and issued a $67.00 target price on shares of Kymera Therapeutics in a report on Tuesday. Finally, Truist Financial increased their price target on shares of Kymera Therapeutics from $53.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $69.75.

Kymera Therapeutics Stock Performance

KYMR stock opened at $61.00 on Friday. The firm has a 50 day moving average price of $53.84 and a 200-day moving average price of $44.88. Kymera Therapeutics has a 52-week low of $19.44 and a 52-week high of $63.96. The firm has a market capitalization of $4.39 billion, a price-to-earnings ratio of -16.99 and a beta of 2.32.

Institutional Trading of Kymera Therapeutics

Several large investors have recently modified their holdings of KYMR. Farther Finance Advisors LLC lifted its holdings in Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after acquiring an additional 540 shares during the period. PNC Financial Services Group Inc. raised its position in Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after acquiring an additional 770 shares during the period. Bessemer Group Inc. boosted its stake in shares of Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after acquiring an additional 815 shares during the last quarter. Osaic Holdings Inc. grew its position in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Kymera Therapeutics in the 2nd quarter worth $73,000.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $59.19, for a total value of $295,950.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Bruce N. Jacobs sold 79,220 shares of the business’s stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.00, for a total transaction of $3,961,000.00. Following the sale, the chief financial officer owned 227,409 shares of the company’s stock, valued at approximately $11,370,450. This represents a 25.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 206,910 shares of company stock worth $11,402,648. 16.01% of the stock is owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.